ALPMF (Astellas Pharma) Other Operating Expense : $2,315 Mil (TTM As of Mar. 2025)

View and export this data going back to 2009. Start your Free Trial

What is Astellas Pharma Other Operating Expense?

Astellas Pharma's Other Operating Expense for the three months ended in Mar. 2025 was $213 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2025 was $2,315 Mil.

Astellas Pharma's quarterly Other Operating Expense increased from Sep. 2024 ($358 Mil) to Dec. 2024 ($1,487 Mil) but then declined from Dec. 2024 ($1,487 Mil) to Mar. 2025 ($213 Mil).

Astellas Pharma's annual Other Operating Expense increased from Mar. 2023 ($1,439 Mil) to Mar. 2024 ($1,722 Mil) and increased from Mar. 2024 ($1,722 Mil) to Mar. 2025 ($2,363 Mil).

Astellas Pharma Other Operating Expense Historical Data

The historical data trend for Astellas Pharma's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Other Operating Expense Chart

Astellas Pharma Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Other Operating Expense

Get a 7-Day Free Trial

1,279.56

989.57

1,438.75

1,721.70

2,362.75

Astellas Pharma Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Other Operating Expense	Get a 7-Day Free Trial															776.07	256.37	358.38	1,486.82	213.27

Astellas Pharma Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,315 Mil.

Astellas Pharma Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Astellas Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMF) » Definitions » Other Operating Expense

Comparable Companies

Traded in Other Exchanges

ALPMY:USA 4503:Japan YPH:Germany

Address

2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411

Website

http://www.astellas.com

Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.